The results of the trial indicated potential safety concerns with JAKis, with major adverse CV events (MACE) and malignancies occurring more often with tofacitinib treatment than with a tumor necrosis factor (TNF) inhibitor, and secondary analyses showing higher rates of adverse events of special interest (AESIs) including herpes zoster and venous thromboembolic events (VTEs) among patients treated with tofacitinib compared with a TNF inhibitor.10 This evidence concerns the gene TNF and herpes zoster.